-
公开(公告)号：US20210121555A1
公开(公告)日：2021-04-29
申请号：US17125555
申请日：2020-12-17
Applicant: Pfizer Inc.
Inventor： Mingming Han , Avvari Krishna Prasad , David Cooper , Wendy Jo Watson
IPC: A61K39/09 , A61K39/385 , A61K39/39
Abstract: The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.
-
公开(公告)号：US10813989B2
公开(公告)日：2020-10-27
申请号：US16704701
申请日：2019-12-05
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00 , A61K39/12 , A61K39/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
公开(公告)号：US10183070B2
公开(公告)日：2019-01-22
申请号：US15883334
申请日：2018-01-30
Applicant: PFIZER INC.
Inventor： Kathrin Ute Jansen , Annaliesa Sybil Anderson , Judith Absalon , Jose Miguel Aste-Amezaga , Johannes Frederik Beeslaar , David Cooper , John Erwin Farley , Leah Diane Fletcher , Shannon Lea Harris , Thomas Richard Jones , Isis Kanevsky , Lakshmi Khandke , Paul Liberator , John Lance Perez , Lynn Marie Phelan , Gary Warren Zlotnick
IPC: A61K39/095 , A61K31/7028 , A61K47/10 , A61K47/18 , C07K14/22 , C07K16/12 , A61K47/26 , A61K47/64 , A61P31/00
Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.
-
14.发明申请公开(公告)号：US20180099039A1
公开(公告)日：2018-04-12
申请号：US15286696
申请日：2016-10-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
公开(公告)号：US20210393764A1
公开(公告)日：2021-12-23
申请号：US17463691
申请日：2021-09-01
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
IPC: A61K39/09 , A61K39/385
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
Patent Agency Ranking
16.发明授权公开(公告)号：US11160855B2
公开(公告)日：2021-11-02
申请号：US15286696
申请日：2016-10-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
-
17.发明申请公开(公告)号：US20160324949A1
公开(公告)日：2016-11-10
申请号：US15110902
申请日：2015-01-15
Applicant: PFIZER INC.
Inventor： Mingming Han , Avvari Krishna Prasad , David Cooper , Wendy Jo Watson
IPC: A61K39/09 , A61K39/39 , A61K39/385
CPC classification number: A61K39/092 , A61K39/385 , A61K39/39 , A61K2039/545 , A61K2039/575 , A61K2039/6037 , A61K2039/6068 , A61K2039/70
Abstract: The invention relates to isolated Streptococcus pneumoniae serotype 15B capsular polysaccharide and processes for their preparation. The invention also relates to immunogenic conjugates comprising Streptococcus pneumoniae serotype 15B capsular polysaccharide covalently linked to a carrier protein, processes for their preparation and immunogenic compositions comprising them.
Abstract translation: 本发明涉及分离的肺炎链球菌血清型15B荚膜多糖及其制备方法。 本发明还涉及包含与载体蛋白共价连接的肺炎链球菌血清型15B荚膜多糖的免疫原性缀合物，其制备方法和包含它们的免疫原性组合物。
-
18.发明申请Immunogenic Compositions Comprising Conjugated Capsular Saccharide Antigens and Uses Thereof 有权包含共轭荚膜糖抗原的免疫原性组合物及其用途公开(公告)号：US20150202309A1
公开(公告)日：2015-07-23
申请号：US14597488
申请日：2015-01-15
Applicant: PFIZER INC.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K47/4833 , A61K39/092 , A61K47/646 , A61K2039/6037 , A61K2039/70 , Y02A50/466
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.
Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。
-
19.发明授权公开(公告)号：US11872274B2
公开(公告)日：2024-01-16
申请号：US17194224
申请日：2021-03-06
Applicant: Pfizer Inc.
Inventor： Emilio Anthony Emini , Wendy Jo Watson , Avvari Krishna Prasad , Mingming Han , Jin-Hwan Kim , Jianxin Gu , Yu-Ying Yang , Rajesh Kumar Kainthan , David Cooper , Michael William Pride , Kathrin Ute Jansen
CPC classification number: A61K39/092 , A61K47/646 , A61K2039/55505 , A61K2039/6037 , A61K2039/70 , Y02A50/30
Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.
-
公开(公告)号：US20230190907A1
公开(公告)日：2023-06-22
申请号：US17812777
申请日：2022-07-15
Applicant: Pfizer Inc.
Inventor： David Cooper , Kathrin Ute Jansen , Michael William Pride
CPC classification number: A61K39/092 , A61K39/39 , A61K2039/55505
Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.
-
-
-
-
-
-
-
-
-
Search Results
27
records
(took 0.027 seconds)
